Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

Key Takeaways

• Enrollment completed: 78 participants across 21 U.S. sites.
• Avexitide holds Breakthrough Therapy and Orphan Drug designations.
• Primary endpoint targets reduction of Level 2/3 hypoglycemia.
• Topline results expected Q3 2026; launch possible 2027.
• PBH affects ~8% of bariatric patients, about 160k U.S.

Summary

Amylyx Pharmaceuticals announced that the pivotal Phase 3 LUCIDITY trial of avexitide has completed enrollment, randomizing and dosing the final participant to bring the total to 78 patients across 21 U.S. sites. The double‑blind, placebo‑controlled study evaluates avexitide, a first‑in‑class GLP‑1 receptor antagonist with FDA Breakthrough Therapy Designation, for post‑bariatric hypoglycemia (PBH). Topline efficacy and safety data are slated for release in the third quarter of 2026, with a commercial launch targeted for 2027 if approval is secured. The trial’s primary endpoint measures reduction in Level 2 and Level 3 hypoglycemic events through week 16.

Pulse Analysis

Post‑bariatric hypoglycemia remains a hidden yet debilitating complication of weight‑loss surgery, striking roughly 8% of the 2 million Americans who have undergone procedures such as Roux‑en‑Y gastric bypass. The condition stems from an exaggerated GLP‑1 response that drives excessive insulin release, leading to sudden, severe drops in blood glucose. Without an FDA‑approved therapy, patients often endure frequent emergency visits, cognitive impairment, and reduced quality of life. Avexitide’s novel mechanism—blocking the GLP‑1 receptor on pancreatic beta cells—directly addresses this pathophysiology, offering a targeted approach that could transform disease management.

The LUCIDITY trial, a multicenter, double‑blind, placebo‑controlled Phase 3 study, enrolled 78 adults with PBH and randomized them 3:2 to daily subcutaneous avexitide or placebo. By focusing on the FDA‑agreed composite endpoint of Level 2 and Level 3 hypoglycemic events through week 16, the study aims to provide robust efficacy evidence while monitoring safety across a 16‑week blinded period and a subsequent 32‑week open‑label extension. The trial’s completion marks a critical milestone, especially given avexitide’s prior Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations, which could accelerate regulatory review if the data confirm significant event reduction.

For investors and the broader endocrine market, avexitide’s potential approval represents a rare opportunity to capture a niche yet sizable therapeutic space. With an estimated 160,000 U.S. patients lacking treatment, a successful launch could generate substantial revenue while reinforcing Amylyx’s reputation for addressing high‑unmet‑need conditions. The anticipated Q3 2026 readout will be closely watched by analysts, as positive results could not only validate the GLP‑1 antagonist strategy but also set the stage for a 2027 commercial rollout, positioning Amylyx as a pioneer in post‑bariatric care.